logo

Halozyme Therapeutics, Inc. (HALO)



Trade HALO now with
  Date
  Headline
9/17/2020 8:12:11 AM Halozyme Announces Poster Presentation Of Data From Roche's Phase 1b Study Evaluating Atezolizumab
9/10/2020 8:04:22 AM Halozyme Unveils Janssen Submission For FDA Approval Of DARZALEX FASPRO For Light Chain Amyloidosis
6/29/2020 12:56:13 PM Roche Gets FDA Approval For Phesgo For Treatment Of HER2-Positive Breast Cancer
6/22/2020 8:09:07 AM Halozyme To Get $10 Mln Milestone Payment From Janssen On Commercial Sale In EU Subcutaneous Formulation Of DARZALEX
6/13/2020 8:54:15 AM Halozyme Therapeutics: Janssen Presents Data From Phase III ANDROMEDA Study
4/26/2020 9:43:44 PM Janssen Submits NDA In Japan For Daratumumab Subcutaneous Formulation Utilizing Halozyme' ENHANZE For Multiple Myeloma
4/3/2020 11:32:34 PM Halo Announces Proposed Acquisition Of Nasalbinoid Natural Devices For C$5.1 Mln
11/13/2019 11:26:28 PM Halozyme Therapeutics Announces Pricing Of Private Offering Of $400 Mln Of Convertible Senior Notes Due 2024
11/4/2019 7:16:13 AM Halozyme Initiates Organizational Restructuring To Close Oncology Operations, Reducing Headcount By About 55%
9/13/2019 1:05:16 AM Halozyme Therapeutics Says Global Phase III FeDeriCa Study Conducted By Genentech Meets Primary Endpoint
7/19/2019 7:07:13 AM Halozyme: Janssen Submits Extension Application To EMA For Subcutaneous Formulation Of DARZALEX Using ENHANZE Technology
7/17/2019 8:05:14 AM Halozyme Says First Clinical Dosing In Argenx's Phase 1 Trial Of Efgartigimod With ENHANZE Drug Delivery Technology
6/25/2019 8:07:35 AM Halozyme Reports CRADA With National Institute Of Allergy And Infectious Diseases For Use Of ENHANZE Drug Delivery Tech
5/22/2019 1:07:27 AM Halozyme Says Argenx Selected Second Target Under ENHANZE Technology Collaboration And License Agreement